Hydroxyurea (HU) is used as a disease-modifying agent in sickle cell disease (SCD). Its
beneficial effects have been ascribed to inhibition of the sickling process through increase of …

Background Patients with sickle cell anaemia (SCA) are routinely managed with folic acid
and paludrine in Nigeria. However, since the licensing of hydroxyurea (HU) by Food and …

Sickle cell disease (SCD) is common in tribal belt of Gujarat, but not addressed effectively as
it should be with effective use of Hydroxyurea, supportive care and counseling. In our single …

Patients with sickle cell disease experience hemolytic anemia and vaso-occlusions that
result in pain, organ injury, and premature mortality. Several prospective studies have …

Background: The pathophysiology of sickle cell disease (SCD) is complex and involves nitric
oxide depletion, increased inflammation/adhesion molecules and vaso-occlusion in addition …

Background: The clinical prospects of hydroxyurea therapy in the management of sickle cell
disease (SCD) require evaluation in the Nigerian setting to develop indigenous guidelines …

Background In Saudi Arabia, sickle cell disease (SCD) is a major public health issue,
especially in the eastern region. Sickle cell patients have major health-related issues …

In this study 21 adults with severe form of sickle cell disease (SCD; sickle cell anaemia, n=
15; Hb S/β°-thal, n= 6) were treated with hydroxyurea (HU) to assess the effectiveness of the …

Background: The vast majority of births with sickle cell anemia occur in Africa 1 and early-life
mortality, generally before age five years, is as high as 90% 2, 3. Hydroxyurea was …

Background and Aim: It is well known that hydroxyurea impacts on clinical and hematologic
indices in sickle cell disease (SCD), we aimed to evaluate the effect of hydroxyurea on …